BioSpace News Archive

Moderna to Present at Chardan’s Virtual 5th Annual Genetic Medicines Conference

NLS Pharmaceutics Ltd. today announced that it has entered into a standby equity distribution agreement, or SEDA, with YA II PN, Ltd.

Revelation Biosciences Inc. (Revelation), a clinical-stage life sciences company that is focused on the development of immunologic‑based therapies for the prevention and treatment of disease, announced today it has received approval from the Federal Agency for Medicines and Health Products (FAMHP) and the local Committee of Medical Ethics in Belgium to conduct a Phase 2b influenza viral challenge study.

Nonagen Bioscience Corp, pioneers in the development of liquid biopsy tests for the detection of human cancers, today announced Oncuria™, their non-invasive bladder cancer test capable of predicting response to therapy, has been granted U.S. Food and Drug Administration (FDA) Breakthrough Device Designation.

Stealth BioTherapeutics Corp announced today the presentation of positive elamipretide data showing improvements in mitochondrial respiration and heart muscle function in tissue from failing human hearts at the International Society for Heart Research North American Section Meeting 2021.

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it earned a $10 million milestone payment from Janssen Pharmaceuticals, Inc.

Oncoinvent Announces Advancement of Radspherin ® to Fourth Dose Level Cohort in Ongoing RAD-18-001 Phase 1 Trial in Ovarian Cancer Patients

Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing cellular therapies for chronic, aging-related, and life-threatening conditions, today announced that the Company’s Lomecel-B research program will be featured in two presentations and a roundtable discussion at the 11th Annual International Conference on Frailty & Sarcopenia Research (ICFSR), taking place virtually September 29 - October 2, 2021.

Lipocine Inc. (Nasdaq: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced the U.S. Food and Drug Administration (“FDA”) has affirmed the resubmission of its New Drug Application (“NDA”) for TLANDO®, its oral testosterone product, will be a Class 1 resubmission.

Caring Cross, a 501(c)(3) non-profit dedicated to accelerating the development of advanced medicines and enabling access to cures for all patients, everywhere, today announced its first initiative focused on CAR-T cell therapy for HIV utilizing manufacturing and distribution models that enable affordability and accessibility of these therapies to diverse patient populations and treatment indications.